Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Cardiac resynchronization therapy devices (CRT)
Implantable cardioverter defibrillators (ICD)
Leads, implantable devices
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
Clinical decision support
March 22, 2013
FDA Approves First Macrocyclic and Ionic Gadolinium-Contrast Agent for MRI
Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a...
February 20, 2013
FDA Committee Recommends Approval of Guerbet’s Macrocyclic, Ionic Gadolinium MRI Contrast Agent
Guerbet announced that the Medical Imaging Drugs Advisory Committee to U.S. Food and Drug Administration (FDA) has...
October 28, 2008
Oxilan Offers Contrast Media for Peripheral Procedures
Oxilan (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity. Its reported...
November 14, 2007
Contrast Agent Lowers Side Effects
Guerbet will feature its Oxilan (ioxilan) injection, a contrast agent that is a nonionic low-viscous and low-osmolar
October 17, 2007
Guerbet Highlights X-Ray Agent, Oxilan
October 18, 2007 - Guerbet will feature at TCT 2007 its x-ray contrast agent, Oxilan (ioxilan) injection, a contrast
September 05, 2007
Guerbet’s Oxilan Wins Frost & Sullivan Award for Contrast Media with Low Side Effects
Guerbet’s flagship X-ray contrast agent, Oxilan (ioxilan) injection, is a contrast agent that is a nonionic, low-visc
August 29, 2006
OXILAN Offers Contrast Media for Peripheral Procedures
OXILAN (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity.
Scranton Gillette Communications
. All Rights Reserved.
Terms and Conditions